Literature DB >> 10987605

Biventricular pacing diminishes the need for implantable cardioverter defibrillator therapy. Ventak CHF Investigators.

S L Higgins1, P Yong, D Sheck, M McDaniel, F Bollinger, M Vadecha, S Desai, D B Meyer.   

Abstract

OBJECTIVES: We sought to test the postulate that biventricular pacing diminishes the need for appropriate tachycardia therapy. We reviewed the frequency of therapy in patients, serving as their own controls, who were enrolled in the Ventak CHF (congestive heart failure) biventricular pacing study.
BACKGROUND: It is well established that both acute and chronic CHF contribute to the need for tachyarrhythmia therapy in recipients of an automatic implantable cardioverter defibrillator (ICD). Synchronized biventricular (BV) pacing is a new and promising therapy for symptomatic improvement of CHF in selected patients (low ejection fraction, intraventricular conduction delay). We postulate that this pacing therapy will diminish the need for tachyarrhythmia therapy.
METHODS: Participants in the Ventak CHF trial received a triple-chamber biventricular ICD with a transvenous right ventricular lead and a left ventricular (LV) lead placed via thoracotomy. Of 54 patients enrolled in the Ventak CHF trial, 32 could be analyzed, with each completing three blinded months programmed to BV VDD pacing and a second randomly assigned three-month period of no pacing.
RESULTS: Of the 32 patients, 13 (41%) received appropriate therapy for a ventricular tachyarrhythmia at least once in the six-month monitoring period postimplant. Five patients (16%) had at least one tachyarrhythmic episode while programmed to BV pacing, whereas 11 (34%) had at least one episode while programmed to no pacing. Three patients (9%) received therapy in both pacing periods, two with BV pacing only. The decrease in necessary tachycardia therapy during the BV pacing period was statistically significant (p = 0.035).
CONCLUSIONS: In patients with standard ICD indications who also have CHF, LV dysfunction, and an intraventricular conduction delay, ICD therapy is less common with BV pacing. The mechanism for this improvement is unclear but may be related to hemodynamic improvement in CHF. Although BV pacing does not obviate the need for an ICD, it does diminish the need for appropriate tachyarrhythmia therapy in selected patients.

Entities:  

Mesh:

Year:  2000        PMID: 10987605     DOI: 10.1016/s0735-1097(00)00795-6

Source DB:  PubMed          Journal:  J Am Coll Cardiol        ISSN: 0735-1097            Impact factor:   24.094


  41 in total

1.  Biventricular pacing for heart failure.

Authors:  Rebecca E Lane; Jamil Mayet; Nicholas S Peters
Journal:  BMJ       Date:  2003-05-03

Review 2.  The emerging role of cardiac resynchronization therapy in milder heart failure: are we implanting too late for response?

Authors:  Jason Bradfield; Noel G Boyle; Ravi Mandapati; Kalyanam Shivkumar
Journal:  Curr Heart Fail Rep       Date:  2012-03

Review 3.  Electrical remodeling in dyssynchrony and resynchronization.

Authors:  Takeshi Aiba; Gordon Tomaselli
Journal:  J Cardiovasc Transl Res       Date:  2012-01-21       Impact factor: 4.132

Review 4.  [Cardiac resynchronization therapy and arrhythmias].

Authors:  D Böcker; R Gradaus
Journal:  Herzschrittmacherther Elektrophysiol       Date:  2005-03

5.  Surgery for ventricular tachycardia in patients undergoing surgical ventricular restoration: the Karolinska approach.

Authors:  Ulrik Sartipy; Anders Albåge; Per Insulander; Dan Lindblom
Journal:  J Interv Card Electrophysiol       Date:  2007-09-09       Impact factor: 1.900

6.  Ventricular arrhythmia, Cheyne-Stokes respiration, and death: observations from patients with defibrillators.

Authors:  A D Staniforth; S C Sporton; M J Early; J A Wedzicha; A W Nathan; R J Schilling
Journal:  Heart       Date:  2005-04-06       Impact factor: 5.994

7.  Potential pro-arrhythmic effect of cardiac resynchronization therapy.

Authors:  Osama Tayeh; Waleed Farouk; Abdo Elazab; Hassan Khald; Antonio Curnis
Journal:  J Saudi Heart Assoc       Date:  2013-05-30

8.  Impact of left ventricular lead position on the incidence of ventricular arrhythmia and clinical outcome in patients with cardiac resynchronization therapy.

Authors:  Thomas Kleemann; Torsten Becker; Margit Strauss; Ngoc Dyck; Steffen Schneider; Udo Weisse; Werner Saggau; Bernd Cornelius; Günter Layer; Karlheinz Seidl
Journal:  J Interv Card Electrophysiol       Date:  2010-03-03       Impact factor: 1.900

9.  Temporary and permanent biventricular pacing via left ventricular epicardial leads implanted during primary cardiac surgery.

Authors:  Hiroyuki Tanaka; Kaoru Okishige; Tomohiro Mizuno; Kazuyuki Kuriu; Fusahiko Itoh; Masato Shimizu; Hideki Akamatsu; Noriyuki Tabuchi; Hirokuni Arai; Makoto Sunamori
Journal:  Jpn J Thorac Cardiovasc Surg       Date:  2002-07

Review 10.  Should all implantable cardioverter defibrillators for ventricular arrhythmias be dual-chamber devices?

Authors:  K L Lee; C P Lau
Journal:  Curr Cardiol Rep       Date:  2001-11       Impact factor: 2.931

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.